1. 927 Sparsentan for treatment of pediatric patients with selected proteinuric glomerular diseases: design of the phase 2 EPPIK study. (17th August 2022) Authors: Trachtman, Howard; Saleem, Moin; Coppo, Rosanna; Rheault, Michelle; He, Ping; Komers, Radko Journal: Archives of disease in childhood Issue: Volume 107(2022)Supplement 2 Page Start: A96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes. (27th July 2016) Authors: Komers, Radko; Xu, Bei; Schneider, Jennifer; Oyama, Terry T Journal: British journal of pharmacology Issue: Volume 173:Number 17(2016:Sep.) Page Start: 2573 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FC 016SPARSENTAN IMPROVES GLOMERULAR BLOOD FLOW AND AUGMENTS PROTECTIVE TISSUE REMODELING IN MOUSE MODELS OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS). (29th May 2021) Authors: Gyarmati, Georgina; Shroff, Urvi; Izuhara, Audrey; Komers, Radko; Bedard, Patricia; Peti-Peterdi, Janos Journal: Nephrology dialysis transplantation Issue: Volume 36(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FP129NEWLY ADMINISTERED IMMUNOSUPPRESSIVE THERAPY (IST) HAS NO IMPACT ON LONG-TERM ANTIPROTEINURIC EFFECT OF SPARSENTAN (SPAR), A DUAL ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONIST, IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): INTERIM ANALYSIS OF THE DUET TRIAL. (18th May 2018) Authors: Trachtman, Howard; Rychlik, Ivan; Haws, Robert; Nester, Carla; Fornoni, Alessia; Komers, Radko Journal: Nephrology dialysis transplantation Issue: Volume 33(2018)Supplement 1 Page Start: i20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. MO033THE DUAL ETAR/AT1R BLOCKER SPARSENTAN SLOWS RENAL DISEASE, IMPROVES LIFESPAN, AND ATTENUATES HEARING LOSS IN ALPORT MICE: COMPARISON WITH LOSARTAN. (6th June 2020) Authors: Cosgrove, Dominic; Dufek, Brianna; Delimont, Duane; Meehan, Daniel; Samuelson, Gina; Hartsock, Jared; Phillips, Grady; Gill, Ruth; Hasson, James; Jenkinson, Celia; Komers, Radko; Gratton, Michael Anne Journal: Nephrology dialysis transplantation Issue: Volume 35(2020)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. MO209: Baseline Characteristics of Adults Enrolled in the Ongoing Phase 3 Randomized, Double-Blind, Active-Control Trial of Sparsentan For the Treatment of Immunoglobulin A Nephropathy (PROTECT). (3rd May 2022) Authors: Wong, Muh; Barratt, Jonathan; Komers, Radko; Mercer, Alex; Rosenberg, Noah Journal: Nephrology dialysis transplantation Issue: Volume 37(2022)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. MO254: Baseline Characteristics of Patients Enrolled in the Ongoing Phase 3 Randomized, Double-Blind, Active-Control Trial of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis (DUPLEX). (3rd May 2022) Authors: Trachtman, Howard; Radhakrishnan, Jai; Komers, Radko; Mercer, Alex; Rosenberg, Noah Journal: Nephrology dialysis transplantation Issue: Volume 37(2022)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. MO255: Sparsentan Protects the Glomerular Basement Membrane and Glycocalyx, and Attenuates Proteinuria in a Rat Model of Focal Segmental Glomerulosclerosis (FSGS). (3rd May 2022) Authors: Bedard, Patricia; Jenkinson, Celia; Komers, Radko Journal: Nephrology dialysis transplantation Issue: Volume 37(2022)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. MO261: Sparsentan, The Dual Endothelin Angiotensin Receptor Antagonist (DEARA), Attenuates Albuminuria and Protects from the Development of Renal Injury to a Greater Extent Than Losartan in the GDDY Mouse Model of IGA Nephropathy: A 16-Week Study. (3rd May 2022) Authors: Nagasawa, Hajime; Suzuki, Hitoshi; Jenkinson, Celia; Ueda, Seiji; Fukao, Yusuke; Nakayama, Maiko; Otsuka, Tomoyuki; Okuma, Teruyuki; Clapper, Wilmelenne; Komers, Radko; Suzuki, Yusuke Journal: Nephrology dialysis transplantation Issue: Volume 37(2022)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P0348THE DUAL ENDOTHELIN ETA AND ANGIOTENSIN AT1 RECEPTOR BLOCKER SPARSENTAN PROTECTS AGAINST THE DEVELOPMENT OF ALBUMINURIA AND GLOMERULOSCLEROSIS IN THE GDDY MOUSE MODEL OF IGA. (6th June 2020) Authors: Nagasawa, Hajime; Suzuki, Hitoshi; Jenkinson, Celia; Ueda, Seiji; Fukao, Yusuke; Nakayama, Maiko; Otsuka, Tomoyuki; Liu, Kai; Komers, Radko; Suzuki, Yusuke Journal: Nephrology dialysis transplantation Issue: Volume 35(2020)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗